Clinical efforts have been made to develop new lung cancer therapies targeting HER/HER2-PI3K-Akt-NF-κB signaling using novel inhibitors of this pathway, such as lapatinib and bortezomib (27,29–32). This evidence concerns the gene ERBB2 and lung cancer.